{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T17:08:30Z","timestamp":1790096910735,"version":"4.0.1"},"reference-count":149,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.drudis.2026.104750","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T06:47:44Z","timestamp":1785307664000},"page":"104750","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Precision targeting in prostate cancer: Mechanistic drivers and the evolving clinical pipeline"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-6348-0230","authenticated-orcid":false,"given":"Pratiksha","family":"Nathe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5626-1486","authenticated-orcid":false,"given":"Yogesh","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3542-2943","authenticated-orcid":false,"given":"Pooja","family":"Ratre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0237-3826","authenticated-orcid":false,"given":"Swanand","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2026.104750_b0005","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.drudis.2026.104750_b0010","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.drudis.2026.104750_b0015","unstructured":"Ferlay JEM et al. Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Accessed 13 May 2026. https:\/\/gco.iarc.who.int\/today; 2024."},{"key":"10.1016\/j.drudis.2026.104750_b0020","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.eururo.2024.11.013","article-title":"Recent patterns and trends in global prostate cancer incidence and mortality: an update","volume":"87","author":"Schafer","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.drudis.2026.104750_b0025","first-page":"136","article-title":"American Cancer Society\u2019s report on the status of cancer disparities in the United States, 2023","volume":"74","author":"Islami","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.drudis.2026.104750_b0030","series-title":"Management of Prostate Cancer: A Multidisciplinary Approach","first-page":"399","article-title":"Management of prostate cancer: EAU guidelines on screening, diagnosis and local primary treatment","author":"Habchi","year":"2017"},{"key":"10.1016\/j.drudis.2026.104750_b0035","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1002\/pros.24918","article-title":"Germline testing for prostate cancer patients: evidence-based evaluation of genes recommended by NCCN guidelines","volume":"85","author":"Xu","year":"2025","journal-title":"Prostate"},{"key":"10.1016\/j.drudis.2026.104750_b0040","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2026.104750_b0045","article-title":"Androgen receptor dynamics in prostate cancer: from disease progression to treatment resistance","volume":"15","author":"Li","year":"2025","journal-title":"Front Oncol"},{"key":"10.1016\/j.drudis.2026.104750_b0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00029","article-title":"Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making","volume":"1","author":"Abida","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.drudis.2026.104750_b0055","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.eururo.2016.08.037","article-title":"DNA repair in prostate cancer: biology and clinical implications","volume":"71","author":"Mateo","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.drudis.2026.104750_b0060","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.eururo.2014.10.022","article-title":"Effect of BRCA mutations on metastatic relapse and cause-specific survival after radical treatment for localised prostate cancer","volume":"68","author":"Castro","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.drudis.2026.104750_b0065","doi-asserted-by":"crossref","DOI":"10.1080\/07853890.2024.2442067","article-title":"Stemness regulation in prostate cancer: prostate cancer stem cells and targeted therapy","volume":"57","author":"Liang","year":"2025","journal-title":"Ann Med"},{"key":"10.1016\/j.drudis.2026.104750_b0070","first-page":"1976","article-title":"Molecular insight into prostate cancer: preventive role of selective bioactive molecules","volume":"13","author":"Jameel","year":"2023","journal-title":"Life (basel)"},{"key":"10.1016\/j.drudis.2026.104750_b0075","first-page":"228","article-title":"Notch and Hedgehog signaling unveiled: crosstalk, roles, and breakthroughs in cancer stem cell research","volume":"15","author":"Iluta","year":"2025","journal-title":"Life (Basel)"},{"key":"10.1016\/j.drudis.2026.104750_b0080","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.eururo.2025.06.013","article-title":"Novel therapeutic strategies for metastatic prostate cancer care","volume":"88","author":"Cimadamore","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.drudis.2026.104750_b0085","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S1470-2045(23)00587-9","article-title":"Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study","volume":"25","author":"Pfister","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.drudis.2026.104750_b0090","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/ng0495-401","article-title":"In vivo amplification of the androgen receptor gene and progression of human prostate cancer","volume":"9","author":"Visakorpi","year":"1995","journal-title":"Nat Genet"},{"key":"10.1016\/j.drudis.2026.104750_b0095","doi-asserted-by":"crossref","first-page":"11952","DOI":"10.3390\/ijms231911952","article-title":"The roles of androgens in humans: biology, metabolic regulation and health","volume":"23","author":"Alemany","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2026.104750_b0100","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a030411","article-title":"Histopathology of prostate cancer","volume":"7","author":"Humphrey","year":"2017","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.drudis.2026.104750_b0105","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1124\/mi.5.3.7","article-title":"Discovery and therapeutic promise of selective androgen receptor modulators","volume":"5","author":"Chen","year":"2005","journal-title":"Mol Interv"},{"key":"10.1016\/j.drudis.2026.104750_b0110","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1053\/j.seminoncol.2007.01.004","article-title":"Adjuvant therapy for stage II and III colorectal cancer","volume":"34","author":"de Gramont","year":"2007","journal-title":"Semin Oncol"},{"key":"10.1016\/j.drudis.2026.104750_b0115","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3390\/biom9020052","article-title":"Biological actions of the Hsp90-binding immunophilins FKBP51 and FKBP52","volume":"9","author":"Zgajnar","year":"2019","journal-title":"Biomolecules"},{"key":"10.1016\/j.drudis.2026.104750_b0120","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/jcb.10683","article-title":"Ras signaling in prostate cancer progression","volume":"91","author":"Weber","year":"2004","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.drudis.2026.104750_b0125","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1210\/me.2009-0310","article-title":"The rules of DNA recognition by the androgen receptor","volume":"24","author":"Denayer","year":"2010","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.drudis.2026.104750_b0130","article-title":"Coregulators determine androgen receptor activity in prostate cancer","volume":"45","author":"Yavuz","year":"2025","journal-title":"Biosci Rep"},{"key":"10.1016\/j.drudis.2026.104750_b0135","first-page":"158","article-title":"Androgen receptor genomic regulation","volume":"2","author":"Jin","year":"2013","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.drudis.2026.104750_b0140","first-page":"6063","article-title":"Molecular and cellular mechanisms of castration resistant prostate cancer","volume":"15","author":"Huang","year":"2018","journal-title":"Oncol Lett"},{"key":"10.1016\/j.drudis.2026.104750_b0145","doi-asserted-by":"crossref","first-page":"e008","DOI":"10.1621\/nrs.06008","article-title":"Diverse roles of androgen receptor (AR) domains in AR-mediated signaling","volume":"6","author":"Claessens","year":"2008","journal-title":"Nucl Recept Signal"},{"key":"10.1016\/j.drudis.2026.104750_b0150","doi-asserted-by":"crossref","DOI":"10.1210\/endocr\/bqag021","article-title":"Androgen metabolism in prostate cancer: recent advances","volume":"167","author":"Sharifi","year":"2026","journal-title":"Endocrinology"},{"key":"10.1016\/j.drudis.2026.104750_b0155","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/nrc4016","article-title":"Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer","volume":"15","author":"Watson","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.drudis.2026.104750_b0160","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.euf.2019.06.004","article-title":"Biochemical recurrence in prostate cancer: the European Association of Urology prostate cancer guidelines panel recommendations","volume":"6","author":"Van den Broeck","year":"2020","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.drudis.2026.104750_b0165","doi-asserted-by":"crossref","first-page":"663","DOI":"10.3390\/cancers16030663","article-title":"Insight into recent advances in degrading androgen receptor for castration-resistant prostate cancer","volume":"16","author":"Chen","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.drudis.2026.104750_b0170","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/35094009","article-title":"The development of androgen-independent prostate cancer","volume":"1","author":"Feldman","year":"2001","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.drudis.2026.104750_b0175","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2026.104750_b0180","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","article-title":"Apalutamide treatment and metastasis-free survival in prostate cancer","volume":"378","author":"Smith","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2026.104750_b0185","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1056\/NEJMoa1815671","article-title":"Darolutamide in nonmetastatic, castration-resistant prostate cancer","volume":"380","author":"Fizazi","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2026.104750_b0190","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1158\/1538-7445.AM2021-1209","article-title":"Comprehensive in vitro characterization of the mechanism of action of EPI-7386, an androgen receptor N-terminal domain inhibitor","volume":"81","author":"Hong","year":"2021","journal-title":"Cancer Res"},{"key":"10.1016\/j.drudis.2026.104750_b0195","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1038\/modpathol.2011.112","article-title":"Folate hydrolase (prostate-specific membrane [corrected] antigen) 1 expression in bladder cancer subtypes and associated tumor neovasculature","volume":"24","author":"Samplaski","year":"2011","journal-title":"Mod Pathol"},{"key":"10.1016\/j.drudis.2026.104750_b0200","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/jcb.10661","article-title":"Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer","volume":"91","author":"Ghosh","year":"2004","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.drudis.2026.104750_b0205","first-page":"81","article-title":"Prostate-specific membrane antigen expression in normal and malignant human tissues","volume":"3","author":"Silver","year":"1997","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.drudis.2026.104750_b0210","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.2967\/jnumed.117.203877","article-title":"A perspective on the evolving story of PSMA biology, PSMA-based imaging, and endoradiotherapeutic strategies","volume":"59","author":"O\u2019Keefe","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1016\/j.drudis.2026.104750_b0215","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0090-4295(98)00278-7","article-title":"Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases","volume":"52","author":"Sweat","year":"1998","journal-title":"Urology"},{"key":"10.1016\/j.drudis.2026.104750_b0220","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/S0090-4295(96)00184-7","article-title":"Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy","volume":"48","author":"Wright","year":"1996","journal-title":"Urology"},{"key":"10.1016\/j.drudis.2026.104750_b0225","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.cell.2017.04.001","article-title":"AKT\/PKB signaling: navigating the network","volume":"169","author":"Manning","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2026.104750_b0230","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.cell.2017.02.004","article-title":"mTOR signaling in growth, metabolism, and disease","volume":"168","author":"Saxton","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2026.104750_b0235","article-title":"PSMA redirects MAPK to PI3K-AKT signaling to promote prostate cancer progression","volume":"4","author":"Caromile","year":"2017","journal-title":"Mol Cell Oncol"},{"key":"10.1016\/j.drudis.2026.104750_b0240","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.eururo.2016.06.021","article-title":"Sensitivity, specificity, and predictors of positive 68Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis","volume":"70","author":"Perera","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.drudis.2026.104750_b0245","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1007\/s00259-012-2298-2","article-title":"Pet imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions","volume":"40","author":"Afshar-Oromieh","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.drudis.2026.104750_b0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2023.108548","article-title":"Boron in cancer therapeutics: an overview","volume":"251","author":"Kulkarni","year":"2023","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.drudis.2026.104750_b0255","doi-asserted-by":"crossref","first-page":"6916","DOI":"10.1158\/1078-0432.CCR-19-1423","article-title":"The role of lineage plasticity in prostate cancer therapy resistance","volume":"25","author":"Beltran","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.drudis.2026.104750_b0260","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2026.104750_b0265","doi-asserted-by":"crossref","first-page":"9364","DOI":"10.7150\/thno.48107","article-title":"Efficacy and safety of 225Ac-PSMA-617 targeted alpha therapy in metastatic castration-resistant prostate cancer patients","volume":"10","author":"Yadav","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.drudis.2026.104750_b0270","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2967\/jnumed.120.260455","article-title":"68Ga-PSMA-11 NDA approval: a novel and successful academic partnership","volume":"62","author":"Carlucci","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1016\/j.drudis.2026.104750_b0275","first-page":"11432","article-title":"Image acquisition and interpretation of 18F-DCFPyL (piflufolastat F18) PET\/CT: how we do it","volume":"30","author":"Rowe","year":"2023","journal-title":"Can J Urol"},{"key":"10.1016\/j.drudis.2026.104750_b0280","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1634\/theoncologist.2020-0028","article-title":"Pilot study of hyperfractionated dosing of lutetium-177-labeled antiprostate-specific membrane antigen monoclonal antibody J591 (177Lu-J591) for metastatic castration-resistant prostate cancer","volume":"25","author":"Niaz","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.drudis.2026.104750_b0285","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS5088","article-title":"Safety and efficacy of AMG 160, a half-life extended BiTE immune therapy targeting prostate-specific membrane antigen (PSMA), and other therapies for metastatic castration-resistant prostate cancer (mCRPC)","volume":"39","author":"Subudhi","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.drudis.2026.104750_b0290","doi-asserted-by":"crossref","first-page":"530.e15","DOI":"10.1016\/j.urolonc.2016.07.005","article-title":"Phase 1\/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer","volume":"34","author":"Milowsky","year":"2016","journal-title":"Urol Oncol"},{"key":"10.1016\/j.drudis.2026.104750_b0295","doi-asserted-by":"crossref","first-page":"3602","DOI":"10.1158\/1078-0432.CCR-20-4528","article-title":"Phase I study of MEDI3726: a prostate-specific membrane antigen-targeted antibody-drug conjugate, in patients with mCRPC after failure of abiraterone or enzalutamide","volume":"27","author":"de Bono","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.drudis.2026.104750_b0300","doi-asserted-by":"crossref","DOI":"10.1177\/17562872231182219","article-title":"Bispecific PSMA antibodies and CAR-T in metastatic castration-resistant prostate cancer","volume":"15","author":"Zarrabi","year":"2023","journal-title":"Ther Adv Urol"},{"key":"10.1016\/j.drudis.2026.104750_b0305","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1200\/JCO.20.01035","article-title":"Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration","volume":"38","author":"Abida","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.drudis.2026.104750_b0310","doi-asserted-by":"crossref","first-page":"12628","DOI":"10.3390\/ijms222312628","article-title":"BRCA mutations in prostate cancer: assessment, implications and treatment considerations","volume":"22","author":"Shah","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2026.104750_b0315","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ccr.2010.05.026","article-title":"Integrative genomic profiling of human prostate cancer","volume":"18","author":"Taylor","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.drudis.2026.104750_b0320","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/nature08467","article-title":"The DNA-damage response in human biology and disease","volume":"461","author":"Jackson","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2026.104750_b0325","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1200\/JCO.19.01638","article-title":"Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study","volume":"38","author":"Antonarakis","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.drudis.2026.104750_b0330","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/nature10760","article-title":"The DNA damage response and cancer therapy","volume":"481","author":"Lord","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2026.104750_b0335","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2026.104750_b0340","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","article-title":"DNA-repair defects and olaparib in metastatic prostate cancer","volume":"373","author":"Mateo","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2026.104750_b0345","doi-asserted-by":"crossref","first-page":"11418","DOI":"10.3390\/ijms241411418","article-title":"DNA damage repair pathways in prostate cancer: a narrative review of molecular mechanisms, emerging biomarkers and therapeutic targets in precision oncology","volume":"24","author":"Grypari","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2026.104750_b0350","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1158\/2159-8290.CD-13-0108","article-title":"A hormone-DNA repair circuit governs the response to genotoxic insult","volume":"3","author":"Goodwin","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1016\/j.drudis.2026.104750_b0355","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1158\/2159-8290.CD-13-0172","article-title":"Androgen receptor signaling regulates DNA repair in prostate cancers","volume":"3","author":"Polkinghorn","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1016\/j.drudis.2026.104750_b0360","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0140-6736(08)61815-2","article-title":"Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7\/SFUO-3): an open randomised phase III trial","volume":"373","author":"Widmark","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2026.104750_b0365","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.annonc.2020.06.011","article-title":"Prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Parker","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.drudis.2026.104750_b0370","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0140-6736(02)09408-4","article-title":"Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial","volume":"360","author":"Bolla","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2026.104750_b0375","doi-asserted-by":"crossref","first-page":"5213","DOI":"10.1158\/1078-0432.CCR-21-1032","article-title":"Ceralasertib (AZD6738), an oral ATR kinase inhibitor, in combination with carboplatin in patients with advanced solid tumours: a phase I study","volume":"27","author":"Yap","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.drudis.2026.104750_b0380","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1158\/1535-7163.MCT-20-1026","article-title":"Novel and highly potent ATR inhibitor M4344 kills cancer cells with replication stress, and enhances the chemotherapeutic activity of widely used DNA damaging agents","volume":"20","author":"Jo","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.drudis.2026.104750_b0385","first-page":"305","article-title":"The current state of molecular testing in the treatment of patients with solid tumors, 2019","volume":"69","author":"El-Deiry","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.drudis.2026.104750_b0390","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1158\/1535-7163.MCT-19-0734","article-title":"Pharmacologic inhibitor of DNA-PK, M3814, potentiates radiotherapy and regresses human tumors in mouse models","volume":"19","author":"Zenke","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.drudis.2026.104750_b0395","doi-asserted-by":"crossref","first-page":"3263","DOI":"10.1158\/1078-0432.CCR-17-3347","article-title":"Evaluation of prexasertib, a checkpoint kinase 1 inhibitor, in a phase Ib study of patients with squamous cell carcinoma","volume":"24","author":"Hong","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.drudis.2026.104750_b0400","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.annonc.2020.12.002","article-title":"Key role for liquid biopsy in the elimination of breast cancer surgery following neoadjuvant therapy","volume":"32","author":"Grinshpun","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.drudis.2026.104750_b0405","doi-asserted-by":"crossref","first-page":"4354","DOI":"10.1200\/JCO.2016.67.5942","article-title":"Phase II study of wee1 inhibitor AZD1775 plus carboplatin in patients with TP53-mutated ovarian cancer refractory or resistant to first-line therapy within 3 months","volume":"34","author":"Leijen","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.drudis.2026.104750_b0410","doi-asserted-by":"crossref","first-page":"3834","DOI":"10.1158\/1078-0432.CCR-21-0329","article-title":"Safety, antitumor activity, and biomarker analysis in a phase I trial of the once-daily wee1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumors","volume":"27","author":"Takebe","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.drudis.2026.104750_b0415","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1593\/neo.121550","article-title":"Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer","volume":"15","author":"Mosquera","year":"2013","journal-title":"Neoplasia"},{"key":"10.1016\/j.drudis.2026.104750_b0420","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/path.4047","article-title":"From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer","volume":"227","author":"Lapuk","year":"2012","journal-title":"J Pathol"},{"key":"10.1016\/j.drudis.2026.104750_b0425","doi-asserted-by":"crossref","first-page":"4698","DOI":"10.1158\/1078-0432.CCR-15-0157","article-title":"SRRM4 expression and the loss of REST activity may promote the emergence of the neuroendocrine phenotype in castration-resistant prostate cancer","volume":"21","author":"Zhang","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.drudis.2026.104750_b0430","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3389\/fonc.2014.00060","article-title":"The many faces of neuroendocrine differentiation in prostate cancer progression","volume":"4","author":"Terry","year":"2014","journal-title":"Front Oncol"},{"key":"10.1016\/j.drudis.2026.104750_b0435","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ccr.2010.05.024","article-title":"Siah2-dependent concerted activity of HIF and FoxA2 regulates formation of neuroendocrine phenotype and neuroendocrine prostate tumours","volume":"18","author":"Qi","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.drudis.2026.104750_b0440","doi-asserted-by":"crossref","first-page":"805","DOI":"10.3390\/cancers16040805","article-title":"Tissue-based diagnostic biomarkers of aggressive variant prostate cancer: a narrative review","volume":"16","author":"Kouroukli","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.drudis.2026.104750_b0445","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s12022-025-09854-3","article-title":"Dll3 expression in neuroendocrine carcinomas and neuroendocrine tumours: insights from a multicentric cohort of 1294 pulmonary and extrapulmonary neuroendocrine neoplasms","volume":"36","author":"Schmitt","year":"2025","journal-title":"Endocr Pathol"},{"key":"10.1016\/j.drudis.2026.104750_b0450","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.ccell.2017.09.004","article-title":"Integrating proteomics and transcriptomics for systematic combinatorial chimeric antigen receptor therapy of AML","volume":"32","author":"Perna","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.drudis.2026.104750_b0455","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2026.1806742","article-title":"Mechanistic insights and molecular therapy for neuroendocrine prostate cancer","volume":"16","author":"Niu","year":"2026","journal-title":"Front Oncol"},{"key":"10.1016\/j.drudis.2026.104750_b0460","doi-asserted-by":"crossref","first-page":"E5576","DOI":"10.1073\/pnas.1722325115","article-title":"Metaproteomics method to determine carbon sources and assimilation pathways of species in microbial communities","volume":"115","author":"Kleiner","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.drudis.2026.104750_b0465","doi-asserted-by":"crossref","DOI":"10.1172\/JCI179998","article-title":"BCL2 expression is enriched in advanced prostate cancer with features of lineage plasticity","volume":"134","author":"Westaby","year":"2024","journal-title":"J Clin Investig"},{"key":"10.1016\/j.drudis.2026.104750_b0470","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1158\/1078-0432.CCR-18-0981","article-title":"Randomized phase II study evaluating Akt blockade with ipatasertib, in combination with abiraterone, in patients with metastatic prostate cancer with and without PTEN loss","volume":"25","author":"de Bono","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.drudis.2026.104750_b0475","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2020.101970","article-title":"WLS-Wnt signaling promotes neuroendocrine prostate cancer","volume":"24","author":"Bland","year":"2021","journal-title":"iScience"},{"key":"10.1016\/j.drudis.2026.104750_b0480","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.4161\/cc.5.17.2982","article-title":"Rest in good times and bad: roles in tumor suppressor and oncogenic activities","volume":"5","author":"Majumader","year":"2006","journal-title":"Cell Cycle"},{"key":"10.1016\/j.drudis.2026.104750_b0485","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nrn1847","article-title":"Notch signalling in vertebrate neural development","volume":"7","author":"Louvi","year":"2006","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.drudis.2026.104750_b0490","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1001\/jamaoncol.2017.0751","article-title":"Associations of luminal and basal subtyping of prostate cancer with prognosis and response to androgen deprivation therapy","volume":"3","author":"Zhao","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.drudis.2026.104750_b0495","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1002\/pros.24707","article-title":"Characterization of structural, biochemical, pharmacokinetic, and pharmacodynamic properties of the LSD1 inhibitor bomedemstat in preclinical models","volume":"84","author":"Jasmine","year":"2024","journal-title":"Prostate"},{"key":"10.1016\/j.drudis.2026.104750_b0500","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1158\/1078-0432.CCR-18-1912","article-title":"A phase II trial of the Aurora kinase A inhibitor alisertib for patients with castration-resistant and neuroendocrine prostate cancer: efficacy and biomarkers","volume":"25","author":"Beltran","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.drudis.2026.104750_b0505","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1038\/s41388-024-03036-x","article-title":"Alternative splicing in prostate cancer progression and therapeutic resistance","volume":"43","author":"Rawat","year":"2024","journal-title":"Oncogene"},{"key":"10.1016\/j.drudis.2026.104750_b0510","doi-asserted-by":"crossref","first-page":"4923","DOI":"10.1158\/1078-0432.CCR-20-4968","article-title":"BET bromodomain inhibition blocks an AR-repressed, E2F1-activated treatment-emergent neuroendocrine prostate cancer lineage plasticity program","volume":"27","author":"Kim","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.drudis.2026.104750_b0515","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/path.6280","article-title":"Co-targeting BET, CBP, and p300 inhibits neuroendocrine signalling in androgen receptor-null prostate cancer","volume":"263","author":"Choo","year":"2024","journal-title":"J Pathol"},{"key":"10.1016\/j.drudis.2026.104750_b0520","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1038\/s41416-021-01435-5","article-title":"Metabolic reprogramming in prostate cancer","volume":"125","author":"Ahmad","year":"2021","journal-title":"Br J Cancer"},{"key":"10.1016\/j.drudis.2026.104750_b0525","first-page":"143","article-title":"Metabolic reprogramming as an emerging mechanism of resistance to endocrine therapies in prostate cancer","volume":"4","author":"Chetta","year":"2021","journal-title":"Cancer Drug Resist"},{"key":"10.1016\/j.drudis.2026.104750_b0530","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.abb.2016.06.020","article-title":"Zinc transporters and signaling in physiology and pathogenesis","volume":"611","author":"Hojyo","year":"2016","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.drudis.2026.104750_b0535","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/path.2809","article-title":"Metabolic alterations and targeted therapies in prostate cancer","volume":"223","author":"Flavin","year":"2011","journal-title":"J Pathol"},{"key":"10.1016\/j.drudis.2026.104750_b0540","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a030569","article-title":"Metabolic vulnerabilities of prostate cancer: diagnostic and therapeutic opportunities","volume":"8","author":"Zadra","year":"2018","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.drudis.2026.104750_b0545","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/path.4518","article-title":"Targeting ASCT2\u2010mediated glutamine uptake blocks prostate cancer growth and tumour development","volume":"236","author":"Wang","year":"2015","journal-title":"J Pathol"},{"key":"10.1016\/j.drudis.2026.104750_b0550","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1172\/JCI75836","article-title":"Targeted inhibition of tumor-specific glutaminase diminishes cell-autonomous tumorigenesis","volume":"125","author":"Xiang","year":"2015","journal-title":"J Clin Invest"},{"key":"10.1016\/j.drudis.2026.104750_b0555","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1073\/pnas.1808834116","article-title":"Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancer","volume":"116","author":"Zadra","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.drudis.2026.104750_b0560","first-page":"111","article-title":"Lipid metabolism in prostate cancer","volume":"2","author":"Wu","year":"2014","journal-title":"Am J Clin Exp Urol"},{"key":"10.1016\/j.drudis.2026.104750_b0565","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41420-025-02354-7","article-title":"SREBF1-based metabolic reprogramming in prostate cancer promotes tumor ferroptosis resistance","volume":"11","author":"Wei","year":"2025","journal-title":"Cell Death Discov"},{"key":"10.1016\/j.drudis.2026.104750_b0570","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1038\/onc.2010.560","article-title":"Wnt\/\u03b2-catenin activation promotes prostate tumor progression in a mouse model","volume":"30","author":"Yu","year":"2011","journal-title":"Oncogene"},{"key":"10.1016\/j.drudis.2026.104750_b0575","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/nrurol.2012.116","article-title":"Wnt\/\u03b2-catenin signalling in prostate cancer","volume":"9","author":"Kypta","year":"2012","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.drudis.2026.104750_b0580","doi-asserted-by":"crossref","first-page":"309","DOI":"10.3390\/biom12020309","article-title":"Exploring the Wnt pathway as a therapeutic target for prostate cancer","volume":"12","author":"Koushyar","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.drudis.2026.104750_b0585","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/nrurol.2017.144","article-title":"WNT signalling in prostate cancer","volume":"14","author":"Murillo-Garz\u00f3n","year":"2017","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.drudis.2026.104750_b0590","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.eururo.2013.08.011","article-title":"Next-generation sequencing of advanced prostate cancer treated with androgen-deprivation therapy","volume":"66","author":"Rajan","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.drudis.2026.104750_b0595","doi-asserted-by":"crossref","first-page":"180","DOI":"10.33594\/000000512","article-title":"Divergent signaling pathways may lead to convergence in cancer therapy \u2013 a review","volume":"56","author":"Qayum","year":"2022","journal-title":"Cell Physiol Biochem"},{"key":"10.1016\/j.drudis.2026.104750_b0600","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/iju.14406","article-title":"Epigenetic modifications in prostate cancer","volume":"28","author":"Sugiura","year":"2021","journal-title":"Int J Urol"},{"key":"10.1016\/j.drudis.2026.104750_b0605","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1440-1746.2010.06447.x","article-title":"Epigenetic regulation of signaling pathways in cancer: role of the histone methyltransferase EZH2","volume":"26","author":"Tsang","year":"2011","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.drudis.2026.104750_b0610","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1101\/gad.1965810","article-title":"Molecular genetics of prostate cancer: new prospects for old challenges","volume":"24","author":"Shen","year":"2010","journal-title":"Genes Dev"},{"key":"10.1016\/j.drudis.2026.104750_b0615","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/nature01075","article-title":"The polycomb group protein EZH2 is involved in progression of prostate cancer","volume":"419","author":"Varambally","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2026.104750_b0620","doi-asserted-by":"crossref","first-page":"851","DOI":"10.3390\/nu14040851","article-title":"Lipid metabolism and epigenetics crosstalk in prostate cancer","volume":"14","author":"Pardo","year":"2022","journal-title":"Nutrients"},{"key":"10.1016\/j.drudis.2026.104750_b0625","article-title":"Molecular mechanisms of targeted therapy resistance in genitourinary tumors: a path to new therapeutic horizons","author":"Chaux","year":"2025","journal-title":"Preprints"},{"key":"10.1016\/j.drudis.2026.104750_b0630","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2025.110000","article-title":"Systematic multi-omics investigation of androgen receptor driven gene expression and epigenetics changes in prostate cancer","volume":"189","author":"Li","year":"2025","journal-title":"Comput Biol Med"},{"key":"10.1016\/j.drudis.2026.104750_b0635","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1158\/2159-8290.CD-21-0576","article-title":"Drug-induced epigenomic plasticity reprograms circadian rhythm regulation to drive prostate cancer toward androgen independence","volume":"12","author":"Linder","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.drudis.2026.104750_b0640","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1210\/er.2014-1034","article-title":"From discovery to function: the expanding roles of long noncoding RNAs in physiology and disease","volume":"36","author":"Sun","year":"2015","journal-title":"Endocr Rev"},{"key":"10.1016\/j.drudis.2026.104750_b0645","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.cell.2019.01.025","article-title":"Widespread and functional RNA circularization in localized prostate cancer","volume":"176","author":"Chen","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2026.104750_b0650","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s10549-014-2974-y","article-title":"Regulation of apoptosis by long non-coding RNA GAS5 in breast cancer cells: implications for chemotherapy","volume":"145","author":"Pickard","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.drudis.2026.104750_b0655","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3390\/diagnostics8030060","article-title":"RNAs as candidate diagnostic and prognostic markers of prostate cancer\u2014from cell line models to liquid biopsies","volume":"8","author":"Lim","year":"2018","journal-title":"Diagnostics (basel)"},{"key":"10.1016\/j.drudis.2026.104750_b0660","series-title":"Cancer","first-page":"15","article-title":"Oxidative stress and prostate cancer","author":"Shiota","year":"2021"},{"key":"10.1016\/j.drudis.2026.104750_b0665","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cmet.2017.10.005","article-title":"Advances in hypoxia-inducible factor biology","volume":"27","author":"Choudhry","year":"2018","journal-title":"Cell Metab"},{"key":"10.1016\/j.drudis.2026.104750_b0670","doi-asserted-by":"crossref","first-page":"3524","DOI":"10.1080\/07391102.2022.2051745","article-title":"Molecular dynamics and 3D-QSAR studies on indazole derivatives as HIF-1\u03b1 inhibitors","volume":"41","author":"Singh","year":"2023","journal-title":"J Biomol Struct Dyn"},{"key":"10.1016\/j.drudis.2026.104750_b0675","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.3390\/cancers11091389","article-title":"Heat shock proteins and ovarian cancer: important roles and therapeutic opportunities","volume":"11","author":"Hoter","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.drudis.2026.104750_b0680","doi-asserted-by":"crossref","first-page":"12668","DOI":"10.1080\/07391102.2023.2175265","article-title":"Molecular docking, 3D-QSAR and simulation studies for identifying pharmacophoric features of indole derivatives as 17\u03b2-hydroxysteroid dehydrogenase type 5 (17\u03b2-HSD5) inhibitors","volume":"41","author":"Kulkarni","year":"2023","journal-title":"J Biomol Struct Dyn"},{"key":"10.1016\/j.drudis.2026.104750_b0685","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103821","article-title":"Polycystic ovary syndrome: current scenario and future insights","volume":"28","author":"Kulkarni","year":"2023","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2026.104750_b0690","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/S0090-4295(00)00824-4","article-title":"Multicenter ProstaScint imaging findings in 2154 patients with prostate cancer.The ProstaScint Imaging Centers","volume":"56","author":"Sodee","year":"2000","journal-title":"Urology"},{"key":"10.1016\/j.drudis.2026.104750_b0695","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta16410","article-title":"Systematic review and economic modelling of the relative clinical benefit and cost-effectiveness of laparoscopic surgery and robotic surgery for removal of the prostate in men with localised prostate cancer","volume":"16","author":"Ramsay","year":"2012","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.drudis.2026.104750_b0700","doi-asserted-by":"crossref","first-page":"12032","DOI":"10.1111\/jcmm.15831","article-title":"The AKR1C3\/AR-V7 complex maintains CRPC tumour growth by repressing B4GALT1 expression","volume":"24","author":"Wang","year":"2020","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.drudis.2026.104750_b0705","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/1741-7015-9-105","article-title":"5-\u03b1 reductase inhibitors and prostate cancer prevention: where do we turn now?","volume":"9","author":"Hamilton","year":"2011","journal-title":"BMC Med"},{"key":"10.1016\/j.drudis.2026.104750_b0710","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.3390\/cancers17172747","article-title":"The safety of abiraterone acetate in patients with metastatic castration-resistant prostate cancer: an individual-participant data meta-analysis based on 14 randomized clinical trials","volume":"17","author":"Shaver","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.drudis.2026.104750_b0715","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1177\/10600280231155441","article-title":"Updates in the treatment of non-metastatic castrate-resistant prostate cancer: the benefit of second-generation androgen receptor antagonists","volume":"57","author":"Hadfield","year":"2023","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.drudis.2026.104750_b0720","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2026.104750_b0725","doi-asserted-by":"crossref","first-page":"497","DOI":"10.2217\/fon.11.23","article-title":"TROPIC: phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer","volume":"7","author":"Oudard","year":"2011","journal-title":"Future Oncol"},{"key":"10.1016\/j.drudis.2026.104750_b0730","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2026.104750_b0735","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2016.10.020","article-title":"Effect of radium-223 dichloride (Ra-223) on hospitalisation: an analysis from the phase 3 randomised alpharadin in symptomatic prostate cancer patients (ALSYMPCA) trial","volume":"71","author":"Parker","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.drudis.2026.104750_b0740","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1200\/JCO.2021.39.6_suppl.126","article-title":"Exploratory gene-by-gene analysis of olaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): PROfound","volume":"39","author":"De Bono","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.drudis.2026.104750_b0745","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.6_suppl.TPS388","article-title":"TRITON2: an international, multicenter, open-label, phase II study of the PARP inhibitor rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD)","volume":"36","author":"Abida","year":"2018","journal-title":"J Clin Oncol"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626001558?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626001558?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:16:51Z","timestamp":1790093811000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644626001558"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":149,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1359644626001558"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104750","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Precision targeting in prostate cancer: Mechanistic drivers and the evolving clinical pipeline","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104750","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104750"}}